861 例非小细胞肺癌患者的 EGFR、KRAS、BRAF 和 PIK3CA 体细胞突变分析。
Somatic mutation analysis of EGFR, KRAS, BRAF and PIK3CA in 861 patients with non-small cell lung cancer.
机构信息
Cancer Institute & Hospital, Chinese Academy of Medical Sciences, Beijing, China.
出版信息
Cancer Biomark. 2011;10(2):63-9. doi: 10.3233/CBM-2012-0233.
The prevalence of EGFR, KRAS, BRAF and PIK3CA somatic mutations in 861 randomly selected Chinese patients with non-small cell lung cancer (NSCLC) was assayed by the SurPlex®-xTAG70plex platform and analyzed. The results showed that the occurrence rates were 41.0, 8.0, 0.7 and 3.7%, respectively. The mutation rates significantly correlated with gender, histology and smoking history. The EGFR exon 19, 20 and 21 mutations were higher in females compared to males (p< 0.001, exon 19 and 21; p=0.018, exon 20), higher in adenocarcinomas compared to other forms of lung cancers (p< 0.001, exon 19 and 21; p=0.035, exon 20), and higher in non-smokers compared to smokers (p< 0.001, exon 19 and 21; p=0.029, exon 20). Conversely, the KRAS mutations were higher in males compared to females (p=0.004), higher in adenocarcinomas compared to other forms of lung cancers (p< 0.001), and higher in smokers compared to non-smokers (p< 0.001). The PIK3CA mutation rate was lower in adenocarcinomas compared to other forms of lung cancers (p=0.003).
861 例随机选择的中国非小细胞肺癌（NSCLC）患者的表皮生长因子受体（EGFR）、KRAS、BRAF 和 PIK3CA 体细胞突变率采用 SurPlex®-xTAG70plex 平台进行检测和分析。结果显示，发生率分别为 41.0%、8.0%、0.7%和 3.7%。突变率与性别、组织学和吸烟史显著相关。EGFR 外显子 19、20 和 21 突变在女性中高于男性（p<0.001，外显子 19 和 21；p=0.018，外显子 20），在腺癌中高于其他类型的肺癌（p<0.001，外显子 19 和 21；p=0.035，外显子 20），在非吸烟者中高于吸烟者（p<0.001，外显子 19 和 21；p=0.029，外显子 20）。相反，KRAS 突变在男性中高于女性（p=0.004），在腺癌中高于其他类型的肺癌（p<0.001），在吸烟者中高于非吸烟者（p<0.001）。PIK3CA 突变率在腺癌中低于其他类型的肺癌（p=0.003）。
Zotero 插件